Drug intelligence / Profile preview

OR-001

Development stage: Preclinical
Lead developer: OccamzRazor

Overview

OR-001 is a preclinical therapeutic candidate being developed by OccamzRazor for the treatment of Parkinson's disease. Identified through the company's AI-driven "Razor" platform, OR-001 is designed to target specific genetic risk factors associated with the disease, including GBA, LRRK2, Alpha-synuclein, and Parkin. The program specifically focuses on "Risk Allele Carriers," a patient population defined by genetic predispositions to Parkinson's disease. As of 2024, the asset remains in the preclinical stage of development, with the goal of providing a disease-modifying intervention for genetically defined subpopulations of Parkinson's patients.

Targets

SNCA (Alpha-synuclein)LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)PRKN (E3 ubiquitin-protein ligase parkin)GBA1 (Glucosylceramidase)

Beyond the preview

Go deeper on OR-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OR-001.

Explore the full profile